Shilpa Medicare receives Eurasia GMP approval for 2 Telangana units

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-12-28T11:30:01+05:30 | Updated On 28 Dec 2024 11:30 AM IST

Shilpa Medicare receives GMP approval from Eurasia

Karnataka: In a BSE filing, Shilpa Medicare informed that its Unit IV and Unit VII in Telangana have received Good Manufacturing Practice (GMP) approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia.

The GMP inspection was conducted by the Ministry of Health, Belarus, in October in both units, as part of the GMP certification process for the Eurasian Economic Union.

This approval will open up significant business opportunities for the company in these countries.

"This is to inform you that Shilpa Medicare Limited, Unit IV, Jadcherla, Telangana, India and Shilpa Medicare Ltd, Unit VII, Nacharam, Hyderabad, Telangana, India had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union in October 2024," the Company stated.

Unit IV of Shilpa Medicare Lid. is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets.

Unit VII of Shilpa Medicare Ltd. is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.

Medical Dialogues team had earlier reported that the Company had received the GMP Certification after the successful closure of the EMA, Europe inspection at Unit 7, Nacharam, Hyderabad, Telangana, India.

Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments.

shilpa medicareshilpa medicare news

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751